Secondary Marketplace / Trade Private Companies / Buy and Sell Maze Therapeutics Stock
Maze Therapeutics

Maze Therapeutics Stock

$551.86MM
Series D Valuation, Dec 2024
Register To Buy and Sell Private Company Shares
For more details on financing and valuation of private companies similar to Maze Therapeutics before its IPO, register or login today.
Please provide a valid email address.
By registering, you agree to Forge’s Terms of Use. Already registered? Sign in

Maze Therapeutics Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Maze Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
12/03/2024 Series D $73.3MM $xx.xx $551.86MM Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
Price per Share
$xx.xx
Shares Outstanding
53,145,012
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
12/03/2024 Series D-1 $41.7MM $xx.xx $551.86MM Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
Price per Share
$xx.xx
Shares Outstanding
37,795,823
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Deep Track Capital, Frazier Life Sciences, Janus Henderson Investors, Logos Capital
01/10/2022 Series C $120.62MM $xx.xx $742.72MM Andreessen Horowitz, Casdin Capital, City Hill Ventures, Direhaus Capital Management, Foresite Capital, General Catalyst, Matrix Capital Management, Moore Strategic Ventures, Ns Investments, Terra Magnum Capital Partners, Woodline Partners
Price per Share
$xx.xx
Shares Outstanding
40,866,704
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Casdin Capital, City Hill Ventures, Direhaus Capital Management, Foresite Capital, General Catalyst, Matrix Capital Management, Moore Strategic Ventures, Ns Investments, Terra Magnum Capital Partners, Woodline Partners
10/25/2019 Series B $158.3MM $xx.xx $596.01MM City Hill Ventures
Price per Share
$xx.xx
Shares Outstanding
57,563,188
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
City Hill Ventures
02/28/2019 Series A $104.99MM $xx.xx $149.98MM Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Foresite Capital, Gv, Third Rock Ventures
Price per Share
$xx.xx
Shares Outstanding
104,985,132
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, Foresite Capital, Gv, Third Rock Ventures
Company Details
Maze Therapeutics is a biotechnology company which offers small molecule precision medicines to patients with common diseases. Their approach integrates human genetics, functional genomics, and therapeutic discovery to identify genetic modifiers that may influence disease progression or outcomes. Maze Therapeutics applies its proprietary Compass™ platform striving to incorporate variant functionalization into each stage of drug development. This company was founded by Mark Daly Ph.D, Stephen Elledge Ph.D, Aaron Gitler Ph.D, Sekar Kathiresan MD, and Jonathan Weissman Ph.D in 2018 and is headquartered in South San Francisco, CA.
Founded
2018
Headquarters
South San Francisco, CA, United States
Post-Money Valuation 3
$551.86MM
Total Funding
$498.9MM
LFR Price per Share
$xx.xx
Last Funding Share Class
Series D

Maze Therapeutics Stock FAQs

To buy and sell Maze Therapeutics stock
Can you buy Maze Therapeutics stock?
You can no longer buy Maze Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
How to buy Maze Therapeutics stock?
You can no longer buy Maze Therapeutics stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
Can you sell Maze Therapeutics stock?
You can no longer sell stock of Maze Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
How to sell Maze Therapeutics stock?
You can no longer sell stock of Maze Therapeutics on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
To learn more about Maze Therapeutics stock
Is Maze Therapeutics a public company?
Maze Therapeutics is now a public company traded on NASDAQ with ticker MAZE.
What is Maze Therapeutics’ stock price?
The stock price of Maze Therapeutics is not currently available.
What is Maze Therapeutics’ stock ticker symbol?
The ticker symbol of Maze Therapeutics is MAZE.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Maze Therapeutics Investors Also Invested in These Private Companies

Terra Magnum Capital Partners
Direhaus Capital Management
City Hill Ventures

Leadership & Board

Leadership

Jason Coloma Ph.D
Chief Executive Officer
Harold Bernstein Ph.D
President & Chief Medical Officer
Amy Bachrodt
Senior Vice President of Finance

Maze Therapeutics News and Media Highlights

Maze Therapeutics looks for IPO lodestar to guide kidney disease assets through clinical trials

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to boost its kidney disease candidates further by going public. The Bay Area-based biotech revealed the planned IPO in a Jan. 7 filing with the Securities and Exchange Commission but did not divulge how many shares it plans to offer nor at what price. Maze applied to be listed on the Nasdaq under the ticker symbol "MAZE," according to the filing.

Maze Therapeutics Raises $115M in Series D Financing

Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, closed a $115m Series D financing that included the conversion of issued convertible notes previously purchased by existing investors.
Browse Insights
Explore Private Companies in the Healthcare software Sector
Sector: Healthcare
Subsector: Healthcare software
Last Funding Round
Company Forge Price Forge Price Change 5 Last Closed Trade Share Class Post-Money Valuation Price per Share Amount Raised
AbridgeAbridge----$xx.xxSeries D$2.75B$xx.xx$250MM
Ambience HealthcareAmbience Healthcare----$xx.xx--------
BenchlingBenchling----$xx.xxSeries F$6.1B$xx.xx$95MM
DeepScribeDeepScribe----$xx.xxSeries B$134.68MM$xx.xx$24MM
InnovaccerInnovaccer$7.39+146.33%$xx.xxSeries F-1$3.88B$xx.xx$153.04MM
Insilico MedicineInsilico Medicine----$xx.xx--------
Rad AIRad AI----$xx.xxSeries C$525.01MM$xx.xx$72.9MM
RapidAIRapidAI$35.00-36.87%$xx.xxSeries C$667.51MM$xx.xx$75MM
VeraDermicsVeraDermics----$xx.xx--------
Viz.aiViz.ai----$xx.xxSeries D$1.28B$xx.xx$120MM

Updated on: Feb 13, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

  1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
  2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
  3. Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
  4. Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
  5. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.